TravelWifi Continues Global Growth, Acquires Barcelona-based Wifivox
11.11.2020 15:05:00 EET | Business Wire | Press release
TravelWifi CEO Wallace Davis announced today the recent acquisition of Barcelona-based Wifivox, the leading provider of mobile Wi-Fi solutions in Spain.
Founded in 2013, Wifivox has offices in Barcelona and Madrid. The company offers rentable Wi-Fi hotspot devices that can be ordered online and then picked up or dropped off at major airports and approximately 2,000 locations throughout Spain. Wifivox has a collaborative agreement with the official Barcelona tourism board and maintains more than 830 B2B partnerships in sectors ranging from events and media production companies to travel agencies and the hospitality industry.
“Few companies in our space have such an enviable reputation for quality and service,” says TravelWifi CEO Wallace Davis. “Having Wifivox join us, further strengthens our goal to become a global leader in mobile Wi-Fi solutions.” Davis also announced that Wifivox CEO and founder Borja Ruiz will remain with the company. “I am looking forward to helping the company expand its footprint across the world,” says Ruiz. “We believe that the Spanish market offers significant opportunities for TravelWifi.”
Wifivox joins TravelWifi in offering portable Wi-Fi solutions for rent or purchase to a global market. The pocket-size devices provide unlimited data at affordable prices, allowing people to stay connected as they travel, work remotely, or even attend virtual classes for school. TravelWifi also offers SIM card solutions, as well as a growing suite of mobile business products such as routers using virtual SIM technology to provide reliable backups to primary physical internet connectivity. Wifivox is the company’s seventh acquisition, joining:
- TEP – Focused on U.S. travelers
- Trinus – Unique SIM card offerings for Latin American B2B
- Yogofi – Hospitality-centric B2C rentals and B2B2C capacity throughout Asia
- Bienvenue – Service-oriented B2B2C offerings for the travel and hospitality industries
- Travelwifi – Paris-based B2C offerings with highly visible airport and event partnerships
- Wifi Republic – A leading provider of mobile Wi-Fi solutions in Indonesia
Previously known as DHI Telecom, the Houston-based parent company rebranded itself as TravelWifi in June. “We examined how we want the world to know us,” says Davis. “The TravelWifi name encapsulates our mission and resonates with our audiences. TravelWifi offers the ability to travel simply, with innovative solutions and connection to what matters. It is the next dimension of travel. Today.”
TravelWifi uses innovative virtual SIM technology to offer a suite of products focused on Wi-Fi connectivity and managed network solutions in more than 130 countries. Customers include business and leisure travelers, organizations dependent on mobile connectivity, as well as tens of thousands of members of the U.S. military and Department of Defense overseas. Its pocket-sized flagship product – the award-winning Sapphire Wi-Fi device – uses CloudSIM technology to create a hotspot with up to 4G LTE speeds. Recent recognition includes:
- Best Military Telecommunications Providers and Most Innovative Travel Gadget by Corporate Vision Telecom Awards, 2019
- Gold in Telecommunications for Sapphire by the Golden Bridge Awards, 2019
- Named Next-Gen Wi-Fi Solution of the Year by Mobile Breakthrough Awards, 2019
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201111005163/en/
Contact information
Debbie M. Edwards
VP of Marketing and Professional Services
1.323.599.1678 | debbie.edwards@travelwifi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom